Erasca, Inc. (ERAS) Stock Analysis & Investment Frameworks
Erasca, Inc. (ERAS) stock analysis on Invetso. Review Erasca, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Erasca, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Erasca, Inc. Key Financial Metrics
- Market Cap: $5.03B
- Revenue: $N/A
- ROE: -80.43%
- ROIC: -37.52%
- Dividend Yield: N/A
About Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Erasca, Inc. Investment Frameworks
Invetso analyzes Erasca, Inc. (ERAS) across the following frameworks:
- Erasca, Inc. 10Y Growth Potential
- Erasca, Inc. Scenario Analysis
- Erasca, Inc. Risks & Opportunities
- Erasca, Inc. Economic Moat
- Erasca, Inc. Business Model
- Erasca, Inc. Management
- Erasca, Inc. SWOT Analysis
- Erasca, Inc. Porter's 5 Forces
- Erasca, Inc. PESTLE Analysis
- Erasca, Inc. ESG Analysis